Web Desc
Innate and Non-Classical Immune Cells in Cancer Immunotherapy
Organizer(s): Nicholas D. Huntington, Eric Vivier, Caroline Robert and Lewis L. Lanier
Date: March 24 - 28, 2019
Location: Keystone Resort, Keystone, CO, USA
Sponsored by BioLegend, Inc.
Summary of Meeting:
Immunotherapy has revolutionized the treatment of many cancer types over the past five years. T cell checkpoint inhibitors have led the way and are the focus of most immunotherapy trials. However innate and non-classical T cells contribute extensively to the tumor infiltrate and significantly impact on the tumor immune response in both the tumor microenvironment and in circulation. This symposium aims to bring together academic and industry opinion leaders in the fields of innate immune cells, natural killer cells, tumor microenvironment, tumor immune suppression, novel immunotherapeutic strategies and clinical cancer immunotherapy to define the next wave of immunotherapy breakthroughs that reach beyond the current T cell checkpoints. The conference offers a unique opportunity for an audience of diverse immunology and cancer research backgrounds to come together and share cutting edge insights into cancer immunology and rational approaches for therapeutic intervention that could be used as be standalone therapy or in combination with T cell checkpoint therapies. A key aim is to bring together experts with complementary interest in cancer immunotherapy that would not normally be drawn to common symposia and foster new dynamic collaborations to advance our understanding of tumor immunity.
Scholarship Deadline: December 4 2018
Discounted Abstract Deadline: December 4 2018
Abstract Deadline: December 13 2018
Discounted Registration Deadline: January 23 2019
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
BioLegend, Inc.
We gratefully acknowledge additional support from these exhibitors at this conference:
American Association for Cancer Research (AACR)
We gratefully acknowledge additional support for this conference from:
AdipoGen Life SciencesInnate PharmaoNKo-innate Pty LtdServier
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Bristol-Myers Squibb Company

Celularity Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA236119-01
Funding for this conference was made possible (in part) by 1R13CA236119-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 24 | 4:00PM - 8:00PM
Arrival and Registration
Room: Longs Peak Foyer


Sunday, March 24 | 6:00PM - 8:00PM
Welcome Mixer
Room: Longs Peak Foyer
No registration fees are used to fund alcohol served at this function.

Monday, March 25 | 7:00AM - 8:00AM
Breakfast
Room: Longs/Quandary Peaks


Monday, March 25 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Grays Peak

Speaker 1 of 2
* Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI, Australia

Monday, March 25 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Grays Peak

Speaker 2 of 2
Ronald Levy, Stanford University, USA
In situ Therapeutic Vaccination with TLR Agonists

Monday, March 25 | 9:00AM - 11:30AM
Clinical and Industry Advances in Cancer Immunotherapy
Room: Grays Peak

Speaker 1 of 6
* Caroline Robert, Institute Gustave Roussy, France
Advances in Melanoma Immunotherapy

Monday, March 25 | 9:00AM - 11:30AM
Clinical and Industry Advances in Cancer Immunotherapy
Room: Grays Peak


Coffee Break

Monday, March 25 | 9:00AM - 11:30AM
Clinical and Industry Advances in Cancer Immunotherapy
Room: Grays Peak

Speaker 3 of 6
Robert J. Johnston, Bristol-Myers Squibb, USA
VISTA Is a pH-Selective PSGL-1 Ligand

Monday, March 25 | 9:00AM - 11:30AM
Clinical and Industry Advances in Cancer Immunotherapy
Room: Grays Peak

Speaker 4 of 6
Stephan Vagner, Institut Curie, France
Translational Control of Immune Checkpoint and Consequences for Cancer Immunotherapy

Monday, March 25 | 9:00AM - 11:30AM
Clinical and Industry Advances in Cancer Immunotherapy
Room: Grays Peak

Speaker 5 of 6
Michael Donio, Arch Oncology, USA
Short Talk: Innate Checkpoint Inhibitor, AO-176, A Next Generation CD47 Antibody with Novel Anti-Cancer Properties

Monday, March 25 | 9:00AM - 11:30AM
Clinical and Industry Advances in Cancer Immunotherapy
Room: Grays Peak

Speaker 6 of 6
Michael Wichroski, Bristol-Myers Squibb, USA
Short Talk: Preclinical Characterization of BMS-986299, a First-In-Class NLRP3 Innate Agonist with Potent Antitumor Activity,
Alone and in Combination with Checkpoint Blockade


Monday, March 25 | 11:30AM - 5:00PM
On Own for Lunch


Monday, March 25 | 11:30AM - 1:00PM
Poster Setup
Room: Longs/Quandary Peaks


Monday, March 25 | 1:00PM - 10:00PM
Poster Viewing
Room: Longs/Quandary Peaks


Monday, March 25 | 3:00PM - 4:30PM
Workshop 1: Recent Advances in Drugging the Innate Immune Re
sponse
Room: Grays Peak

Speaker 1 of 7
* Robert J. Johnston, Bristol-Myers Squibb, USA

Monday, March 25 | 3:00PM - 4:30PM
Workshop 1: Recent Advances in Drugging the Innate Immune Re
sponse
Room: Grays Peak

Speaker 2 of 7
Amit Kumar, Johns Hopkins University, USA
Protein Engineering of s-DAB389-IL2 for Cancer Immunotherapy and Reduced Vascular Leak Syndrome

Monday, March 25 | 3:00PM - 4:30PM
Workshop 1: Recent Advances in Drugging the Innate Immune Re
sponse
Room: Grays Peak

Speaker 3 of 7
Elizabeth Sturgill, Providence Cancer Institute, USA
Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival

Monday, March 25 | 3:00PM - 4:30PM
Workshop 1: Recent Advances in Drugging the Innate Immune Re
sponse
Room: Grays Peak

Speaker 4 of 7
Monia Draghi, Compass Therapeutics, USA
Preclinical Characterization of NKp30xBCMA, a Novel Class of NK-Cell Engagers

Monday, March 25 | 3:00PM - 4:30PM
Workshop 1: Recent Advances in Drugging the Innate Immune Re
sponse
Room: Grays Peak

Speaker 5 of 7
Brian J. Francica, Tempest Therapeutics, USA
Magnitude of Therapeutic STING Activation Critically Impacts CD8+ T Cell-Mediated Anti-Tumor Immunity

Monday, March 25 | 3:00PM - 4:30PM
Workshop 1: Recent Advances in Drugging the Innate Immune Re
sponse
Room: Grays Peak

Speaker 6 of 7
Carina Hage, Roche Diagnostics GmbH, Germany
Sorafenib Initiates Macrophage-Natural Killer Cell Crosstalk by Macrophage Pyroptosis

Monday, March 25 | 3:00PM - 4:30PM
Workshop 1: Recent Advances in Drugging the Innate Immune Re
sponse
Room: Grays Peak

Speaker 7 of 7
Manuela Zonca, PsiOxus Therapeutics, UK
NG-641: A Tumor Stroma Targeting Transgene-Bearing Oncolytic Virus

Monday, March 25 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Monday, March 25 | 5:00PM - 7:15PM
Myeloid Cells
Room: Grays Peak

Speaker 1 of 6
* Stefani Spranger, Massachusetts Institute of Technology, USA
Cross-Presenting Dendritic Cells within the Tumor Microenvironment

Monday, March 25 | 5:00PM - 7:15PM
Myeloid Cells
Room: Grays Peak

Speaker 2 of 6
Dmitry I. Gabrilovich, AstraZeneca, USA
Myeloid-Derived Suppressor Cells in Cancer: Targeting Opportunities

Monday, March 25 | 5:00PM - 7:15PM
Myeloid Cells
Room: Grays Peak

Speaker 3 of 6
Weiping Zou, University of Michigan, USA
Myeloid Cells in Cancer Immunity and Cancer Stemness

Monday, March 25 | 5:00PM - 7:15PM
Myeloid Cells
Room: Grays Peak

Speaker 4 of 6
Matthias Ernst, Olivia Newton-John Cancer Research Institute, Australia
Short Talk: Targeting the Myeloid-Cell Specific Kinase HCK Improves Anti-Tumor Immunity

Monday, March 25 | 5:00PM - 7:15PM
Myeloid Cells
Room: Grays Peak

Speaker 5 of 6
Katherine Brempelis, Seattle Children's Research Institute, USA
Short Talk: Programming Macrophages to Alter the Solid Tumor Microenvironment

Monday, March 25 | 5:00PM - 7:15PM
Myeloid Cells
Room: Grays Peak

Speaker 6 of 6
Anje Cauwels, VIB and Ghent University, Belgium
Short Talk: Specific Targeting of Type I Interferon to the Tumor Microenvironment or to Dendritic Cells as a Novel, Generic, Safe Cancer Immunotherapy

Monday, March 25 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Longs/Quandary Peaks
No registration fees are used to fund alcohol served at this function.

Monday, March 25 | 7:30PM - 10:00PM
Poster Session 1
Room: Longs/Quandary Peaks


Tuesday, March 26 | 7:00AM - 8:00AM
Breakfast
Room: Longs/Quandary Peaks


Tuesday, March 26 | 8:00AM - 11:00AM
ADCC and Phagocytosis
Room: Grays Peak

Speaker 1 of 7
* Irving L. Weissman, Stanford University, USA
CD47 in Tumor Immunity

Tuesday, March 26 | 8:00AM - 11:00AM
ADCC and Phagocytosis
Room: Grays Peak

Speaker 2 of 7
Sergio A. Quezada, University College London, UK
Impact of Fc/FcR Interaction on the Activity of Immune Modulatory Antibodies

Tuesday, March 26 | 8:00AM - 11:00AM
ADCC and Phagocytosis
Room: Grays Peak


Coffee Break

Tuesday, March 26 | 8:00AM - 11:00AM
ADCC and Phagocytosis
Room: Grays Peak

Speaker 4 of 7
Mark S. Cragg, University of Southampton, UK
Tumour:Myeloid Interactions Mediating Antibody Immunotherapy

Tuesday, March 26 | 8:00AM - 11:00AM
ADCC and Phagocytosis
Room: Grays Peak

Speaker 5 of 7
André Veillette, Institut de Recherches Cliniques de Montreal, Canada
Novel Roles of SLAM Family Receptors in Innate and Innate-Like Immune Cells

Tuesday, March 26 | 8:00AM - 11:00AM
ADCC and Phagocytosis
Room: Grays Peak

Speaker 6 of 7
Nicholas Wilson, Gilead Biosciences, Inc., USA
Short Talk: Selective Fc?R Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens

Tuesday, March 26 | 8:00AM - 11:00AM
ADCC and Phagocytosis
Room: Grays Peak

Speaker 7 of 7
Darienne R. Myers, Revolution Medicines, USA
Short Talk: Shp1 Loss Drives Robust Anti-Tumor Immunity and Enhances Macrophage Effector Function

Tuesday, March 26 | 11:00AM - 5:00PM
On Own for Lunch


Tuesday, March 26 | 11:00AM - 1:00PM
Poster Setup
Room: Longs/Quandary Peaks


Tuesday, March 26 | 1:00PM - 10:00PM
Poster Viewing
Room: Longs/Quandary Peaks


Tuesday, March 26 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Tuesday, March 26 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Grays Peak

Speaker 1 of 5
Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, USA
NK Cell-Mediated Cytotoxicity Contributes to Tumor Control by a Cytostatic Drug Combination

Tuesday, March 26 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Grays Peak

Speaker 2 of 5
* Ursula Grohmann, University of Perugia, Italy
An Intracellular Spatial Dynamics Dictates the Catalytic Versus Signaling Function of IDO1 in Dendritic Cells

Tuesday, March 26 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Grays Peak

Speaker 3 of 5
Eric D. Frontera, Michigan State University, USA
Short Talk: IgA Fc-Folate Conjugate Activates and Recruits Neutrophils to Directly Target Triple-Negative Breast Cancer Cells

Tuesday, March 26 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Grays Peak

Speaker 4 of 5
Chelsea Lassiter, University of Minnesota, USA
Short Talk: Targeting STAT3 in Breast Cancer Models

Tuesday, March 26 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Grays Peak

Speaker 5 of 5
Ying Jiang, University of Virginia, USA
Short Talk: Multicellular Immunological Microenvironment Drives Tumor Initiation and Progression in Medulloblastoma

Tuesday, March 26 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Longs/Quandary Peaks
No registration fees are used to fund alcohol served at this function.

Tuesday, March 26 | 7:30PM - 10:00PM
Poster Session 2
Room: Longs/Quandary Peaks


Wednesday, March 27 | 7:00AM - 8:00AM
Breakfast
Room: Longs/Quandary Peaks


Wednesday, March 27 | 8:00AM - 11:00AM
Innate Checkpoints
Room: Grays Peak

Speaker 1 of 7
Carla V. Rothlin, Yale University, USA
Innate Immune Checkpoints in Cancer

Wednesday, March 27 | 8:00AM - 11:00AM
Innate Checkpoints
Room: Grays Peak

Speaker 2 of 7
Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI, Australia
Natural Killer Cell Response to Cancer

Wednesday, March 27 | 8:00AM - 11:00AM
Innate Checkpoints
Room: Grays Peak


Coffee Break

Wednesday, March 27 | 8:00AM - 11:00AM
Innate Checkpoints
Room: Grays Peak

Speaker 4 of 7
Alberto Mantovani, Humanitas University, Italy
New Vistas on Tumor-Associated Macrophages and Interaction with NK cells

Wednesday, March 27 | 8:00AM - 11:00AM
Innate Checkpoints
Room: Grays Peak

Speaker 5 of 7
* Lewis L. Lanier, University of California, San Francisco, USA
NK Cell Memory to Cancer

Wednesday, March 27 | 8:00AM - 11:00AM
Innate Checkpoints
Room: Grays Peak

Speaker 6 of 7
Dan Fu Ruan, Icahn School of Medicine at Mount Sinai, USA
Short Talk: HLA-E Expression as a Major Determinant of Antitumor Function

Wednesday, March 27 | 8:00AM - 11:00AM
Innate Checkpoints
Room: Grays Peak

Speaker 7 of 7
Angela L. Tata, Brown University, USA
Short Talk: KLRG1 as a Novel Target for Immune Checkpoint Blockade

Wednesday, March 27 | 11:00AM - 1:00PM
Poster Setup
Room: Longs/Quandary Peaks


Wednesday, March 27 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, March 27 | 1:00PM - 10:00PM
Poster Viewing
Room: Longs/Quandary Peaks


Wednesday, March 27 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Wednesday, March 27 | 5:00PM - 7:15PM
Immune Evasion and Metastasis
Room: Grays Peak

Speaker 1 of 7
* Caroline Robert, Institute Gustave Roussy, France

Wednesday, March 27 | 5:00PM - 7:15PM
Immune Evasion and Metastasis
Room: Grays Peak

Speaker 2 of 7
Kai W. Wucherpfennig, Dana-Farber Cancer Institute, USA
Targeting Immune Evasion from the MICA-NKG2D Pathway

Wednesday, March 27 | 5:00PM - 7:15PM
Immune Evasion and Metastasis
Room: Grays Peak

Speaker 3 of 7
Ilaria Malanchi, Francis Crick Institute, UK
Neutrophils in the Metastatic Niche

Wednesday, March 27 | 5:00PM - 7:15PM
Immune Evasion and Metastasis
Room: Grays Peak

Speaker 4 of 7
Sohail F. Tavazoie, Rockefeller University, USA
Metastatic Progression as a Model for Understanding Anti-Tumor Immunity

Wednesday, March 27 | 5:00PM - 7:15PM
Immune Evasion and Metastasis
Room: Grays Peak

Speaker 5 of 7
Sumera Rizvi, Mayo Clinic, USA
Short Talk: PD-L1+ Protumor Macrophages Facilitate Tumor Progression in Murine Cholangiocarcinoma

Wednesday, March 27 | 5:00PM - 7:15PM
Immune Evasion and Metastasis
Room: Grays Peak

Speaker 6 of 7
Debolina Ganguly, University of Texas Southwestern Medical Center, USA
Short Talk: Pleiotrophin and Midkine Promote Metastasis in Pre-Clinical Models of Breast Cancer

Wednesday, March 27 | 5:00PM - 7:15PM
Immune Evasion and Metastasis
Room: Grays Peak

Speaker 7 of 7
Hin Ching Lo, Baylor College of Medicine, USA
Short Talk: Circulating Tumor Cell Clusters Exhibit Enhanced Immune Evasion from Natural Killer Cells

Wednesday, March 27 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Longs/Quandary Peaks
No registration fees are used to fund alcohol served at this function.

Wednesday, March 27 | 7:30PM - 10:00PM
Poster Session 3
Room: Longs/Quandary Peaks


Thursday, March 28 | 7:00AM - 8:00AM
Breakfast
Room: Longs/Quandary Peaks


Thursday, March 28 | 8:00AM - 11:15AM
NK Cells and ILCs
Room: Grays Peak

Speaker 1 of 7
* Eric Vivier, Aix Marseille University, France
Targeting NK Cells in Cancer

Thursday, March 28 | 8:00AM - 11:15AM
NK Cells and ILCs
Room: Grays Peak

Speaker 2 of 7
Xiaokui Zhang, Celularity Inc., USA
Adoptive NK Cell Therapies

Thursday, March 28 | 8:00AM - 11:15AM
NK Cells and ILCs
Room: Grays Peak


Coffee Break

Thursday, March 28 | 8:00AM - 11:15AM
NK Cells and ILCs
Room: Grays Peak

Speaker 4 of 7
David H. Raulet, University of California, Berkeley, USA
Activation and Inhibition of NK Cells in the Tumor Microenvironment, and Applications to Therapy

Thursday, March 28 | 8:00AM - 11:15AM
NK Cells and ILCs
Room: Grays Peak

Speaker 5 of 7
Adelheid Cerwenka, University of Heidelberg, Germany
Unleashing Potent NK Cell Anti-Tumor Activity in Solid Tumors

Thursday, March 28 | 8:00AM - 11:15AM
NK Cells and ILCs
Room: Grays Peak

Speaker 6 of 7
Karl-Johan Malmberg, University of Oslo, Norway
Short Talk: Subset Plasticity and Functional Reprogramming during Natural Killer Cell Homeostasis

Thursday, March 28 | 8:00AM - 11:15AM
NK Cells and ILCs
Room: Grays Peak

Speaker 7 of 7
Robin S. Lindsay, University of Virginia, USA
Short Talk: NK Cells Increase T Cell Infiltration and Antigen Presenting Cell Maturation within Melanoma Tumors

Thursday, March 28 | 11:00AM - 5:00PM
On Own for Lunch


Thursday, March 28 | 3:00PM - 4:30PM
Workshop 2: Cellular Therapies & Biomarkers
Room: Grays Peak

Speaker 1 of 7
* Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI, Australia

Thursday, March 28 | 3:00PM - 4:30PM
Workshop 2: Cellular Therapies & Biomarkers
Room: Grays Peak

Speaker 2 of 7
Chao Guo, Nkarta Therapeutics, USA
Short Talk: NK Cells Engineered to Express a Bispecific CD123/NKG2D Chimeric Antigen Receptor (CAR) and IL-15 As
Off-the-Shelf Therapy for Acute Myeloid Leukemia


Thursday, March 28 | 3:00PM - 4:30PM
Workshop 2: Cellular Therapies & Biomarkers
Room: Grays Peak

Speaker 3 of 7
Xiao-Hua Li, University of California, San Diego, USA
Short Talk: Switchable Chimeric Antigen Receptor-Engineered iPSC-Derived Natural Killer Cells

Thursday, March 28 | 3:00PM - 4:30PM
Workshop 2: Cellular Therapies & Biomarkers
Room: Grays Peak

Speaker 4 of 7
Michael Klichinsky, Carisma Therapeutics, USA
Human Chimeric Antigen Receptor (CAR) Macrophages for Cancer Immunotherapy

Thursday, March 28 | 3:00PM - 4:30PM
Workshop 2: Cellular Therapies & Biomarkers
Room: Grays Peak

Speaker 5 of 7
Huang Zhu, University of California, San Diego, USA
Deletion of CISH in Human Stem Cell Derived Natural Killer Cells Promotes in vivo Persistence and Enhances Anti-Tumor Activity

Thursday, March 28 | 3:00PM - 4:30PM
Workshop 2: Cellular Therapies & Biomarkers
Room: Grays Peak

Speaker 6 of 7
Yago Pico de Coaña, Karolinska Institutet, Sweden
Monitoring Advanced Melanoma Patients after Checkpoint Blockade: NK Cells and MDSCs as Predictive Biomarkers

Thursday, March 28 | 3:00PM - 4:30PM
Workshop 2: Cellular Therapies & Biomarkers
Room: Grays Peak

Speaker 7 of 7
Richard P. Tobin, University of Colorado Anschutz Medical Campus, USA
Mucosal-Associated Invariant T Cells as a Novel Marker of Response to Anti-PD1 Therapy in Melanoma Patients

Thursday, March 28 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Thursday, March 28 | 5:00PM - 6:45PM
Emerging Techniques in Immunotherapy
Room: Grays Peak

Speaker 1 of 5
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Combination Immunotherapies Acting through Innate Immunity

Thursday, March 28 | 5:00PM - 6:45PM
Emerging Techniques in Immunotherapy
Room: Grays Peak

Speaker 2 of 5
* Thomas Gebhardt, Doherty Institute for Infection and Immunity, Australia
Imaging Melanoma Immune Homeostasis in the Skin

Thursday, March 28 | 5:00PM - 6:45PM
Emerging Techniques in Immunotherapy
Room: Grays Peak

Speaker 3 of 5
Bjorn Onfelt, KTH - Royal Institute of Technology, Sweden
Short Talk: Microchip Platform for Imaging-Based Efficacy Testing of Cells and Reagents for Immunotherapy

Thursday, March 28 | 5:00PM - 6:45PM
Emerging Techniques in Immunotherapy
Room: Grays Peak

Speaker 4 of 5
Davide Bernareggi, University of California, San Diego, USA
Short Talk: Use of CRISPR/Cas9 Screening System to Identify Genes that Regulate NK Cell-Mediated Killing of Glioblastoma
and Meningioma


Thursday, March 28 | 5:00PM - 6:45PM
Emerging Techniques in Immunotherapy
Room: Grays Peak

Speaker 5 of 5
Adam Jelinski, Weizmann Institute, Israel
Short Talk: Single-Cell Analysis Illustrates Discrete Cellular Dynamics Generated Between A Pure Checkpoint Blocking Antibody, aCTLA4 mIgG1, and a Dual-Activity aCTLA4 mIgGa2 with Additional FcgR Engaging Activity

Thursday, March 28 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Grays Peak


Thursday, March 28 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Longs/Quandary Peaks
No registration fees are used to fund alcohol served at this function.

Thursday, March 28 | 8:00PM - 11:00PM
Entertainment
Room: Longs/Quandary Peaks
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, March 28 | 8:00PM - 11:00PM
Cash Bar
Room: Longs/Quandary Peaks


Friday, March 29 | 10:24AM - 10:24AM
Departure


*Session Chair.